ARA-290 Research: What 98 Studies Show (2026) | RetatrutideCompare

ARA-290 — 98 studies indexed on PubMed. Selective agonist of the innate repair receptor (EPOR/CD131 heteromer) without binding the canonical EPOR — provides EPO's tissue-protective effects without erythropoiesis. Half-life: ~2 minutes (i.v.). FDA status: Investigational.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on ARA-290?

There are approximately 98 studies indexed on PubMed that mention ARA-290 (Cibinetide, Helix B Surface Peptide), based on a search last updated 2026-06-18.

Is ARA-290 FDA-approved?

FDA status: Investigational.

How does ARA-290 work?

Selective agonist of the innate repair receptor (EPOR/CD131 heteromer) without binding the canonical EPOR — provides EPO's tissue-protective effects without erythropoiesis.

Selective agonist of the innate repair receptor (EPOR/CD131 heteromer) without binding the canonical EPOR — provides EPO's tissue-protective effects without erythropoiesis.

Reference facts

Also known as
Cibinetide, Helix B Surface Peptide
Category
Healing & Tissue Repair
Mechanism of action
Selective agonist of the innate repair receptor (EPOR/CD131 heteromer) without binding the canonical EPOR — provides EPO's tissue-protective effects without erythropoiesis.
Targets
EPOR/CD131
Indications under research or approved
Sarcoidosis-related small fibre neuropathy (Phase 2/3), Diabetic neuropathy (research)
Regulatory status (reference entry)
Investigational
Half-life
~2 minutes (i.v.)
Sequence
QEQLERALNSS
Sequence notes
11-residue peptide derived from helix B of erythropoietin (EPO).
Molecular weight (Da)
1257
Originator / sponsor
Araim Pharmaceuticals
First reported
2008

Primary References

Explore research articles about ARA-290

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.